SAGA Diagnostics provides ultra-sensitive, blood-based molecular residual disease (MRD) detection and monitoring tests for cancer patients. The company's flagship platform, Pathlight, uses tumor whole-genome sequencing and personalized digital PCR assays to detect circulating tumor DNA, primarily serving clinicians and biopharmaceutical partners for early cancer detection and treatment tracking.
Subscribe to see Saga Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Saga Bio, Inc. is a biotechnology company headquartered in Branford, United States. Its most recent funding round raised $60,000 in May 2022. Xcout tracks 14 named people at Saga Bio, Inc., including Brian Dow (Chief Financial Officer).
As of 16 November 2026. Source: Xcout Intel.
8 more named people on record for Saga Bio, Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $60,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Saga Bio, Inc.'s closest competitors — see the full list of competitors and alternatives →
Predicta Biosciences is a precision oncology company that builds a molecular insights platform for blood cancer care. By utilizing a single blood sample, the company integrates multiomics and liquid biopsies to generate longitudinal genomic and immune insights for diagnostics.
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Pathwork Diagnostics developed molecular diagnostic tests for cancer, notably the Tissue of Origin test, which analyzes tumor gene-expression patterns to help identify the likely primary site of metastatic cancers when the origin is unknown. Its products served pathologists and oncologists managing patients with cancers of unknown primary.
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Capio Biosciences is an oncology diagnostics company that develops advanced technologies for capturing and analyzing circulating tumor cells (CTCs) from whole blood. Its proprietary CapioCyte platform offers enhanced sensitivity compared to traditional methods, serving as a research tool designed to help oncologists make informed cancer treatment decisions.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Saga Bio, Inc.? Suggest a correction · Work at Saga Bio, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.